TITLE

Restrictive access to clopidogrel and mortality following coronary stent implantation

AUTHOR(S)
Sheehy, Odile; LeLorier, Jacques; Rinfret, Stéphane
PUB. DATE
February 2008
SOURCE
CMAJ: Canadian Medical Association Journal;2/12/2008, Vol. 178 Issue 4, p413
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In Canada, access to clopidogrel is restricted by most provincial drug insurance plans in order to contain costs. Until April 2007, the Régie de l'assurance maladie du Québec (RAMQ) Prescription Drug Insurance Plan reviewed special access forms before approving reimbursement for clopidogrel prescriptions. We investigated the impact of this restrictive process on patient's filling of prescriptions and on all-cause mortality following coronary stenting. Methods: We analyzed prescriptions filled and all-cause mortality in the year following a percutaneous coronary intervention among patients who underwent stent implantation between January 2000 and September 2004. We obtained administrative data from the RAMQ databases. We included patients who filled at least 1 prescription for a nonrestricted cardiovascular drug after hospital discharge. We used Cox proportional models to compare mortality rates as a function of delayed or absent outpatient clopidogrel therapy. Results: Of 13 663 patients, 1571 (11.5%) did not fill any clopidogrel prescription despite filling at least 1 nonrestricted cardiovascular drug prescription after a percutaneous coronary intervention, and 1174 (8.6%) patients filled their clopidogrel prescription with a delay of at least 1 day (median delay 5 days) after filling the nonrestricted cardiovascular drug prescription. After controlling for pertinent covariables, not filling a clopidogrel prescription (hazard ratio [HR] 1.70, 95% confidence interval [CI] 1.35-2.15) and filling with a delay (HR 1.34, 95% CI 1.01–1.80) were associated with a significant increase in all-cause mortality. Interpretation: Restricted access to clopidogrel was associated with about 20% of patients either not receiving clopidogrel or receiving therapy after a delay. Delay or absence of clopidogrel therapy increased the risk of all-cause mortality after percutaneous coronary intervention with stenting.
ACCESSION #
28799782

 

Related Articles

  • The electronic prescription conundrum: Why “e-Rx” isn't so “e-Z”. Ridinger, M. H. T. // Clinical Pharmacology & Therapeutics;Jan2007, Vol. 81 Issue 1, p13 

    Errors and inefficiencies related to the fulfillment of prescription medications are causes of significant morbidity, mortality, and cost within the health-care system. But what is being done to replace handwritten prescriptions with safer e-prescriptions systems, known as e-Rx, and how do they...

  • Who's calling THE SHOTS? Rollins, Gina // Modern Physician;Jun2003, Vol. 7 Issue 6, p18 

    Discusses the attempt of pharmacy and therapeutics (P&T) committees to set formularies determining drugs' safety and efficacy standards while steering clear of outside influence. Attempts to change a formulary decision made by the P&T committee of Tufts Health Plan in Boston; Information on how...

  • Survey of hospitals for guidelines, policies, and protocols for anticoagulants. Vats, Vikrant; Nutescu, Edith A.; Theobald, John C.; Wojtynek, Jeffrey E.; Schumock, Glen T. // American Journal of Health-System Pharmacy;6/1/2007, Vol. 64 Issue 11, p1203 

    Purpose. A survey of community hospitals that are part of a national group purchasing organization (GPO) was conducted to assess the formulary status of currently available anticoagulants, assess the current status of anticoagulant prescribing guidelines and the existing scope of such...

  • Leader: You get what you pay for in a health service.  // GP: General Practitioner;8/12/2005, p23 

    This article reports that in 2004, there was a 30 percent increase in lipid-lowering drug dispensing, an almost 10 percent rise for diabetes drugs and nearly a 5 percent rise for inhaled corticosteroids. In total, there was a 5.3 percent rise in items dispensed. As a result, the cost of...

  • Innocent parties or devious drug users: the views of primary healthcare practitioners with respect to those who misuse prescription drugs. Butler, Rachael; Sheridan, Janie // Harm Reduction Journal;2010, Vol. 7, p21 

    Background: Many health professionals engage in providing health services for drug users; however, there is evidence of stigmatisation by some health professionals. Prescription drug misusers as a specific group, may also be subject to such judgment. This study aimed to understand issues for...

  • Supplementary prescribing: Pilot of a clinical management plan template. Tanna, NK; Pitkin, J // Journal of the British Menopause Society;2004 Supplement, Vol. 10, p16 

    An abstract of the article "Supplementary prescribing: Pilot of a clinical management plan template," by N. K. Tanna, J. Pitkin, and the Northwick Park Menopause Clinical and Research Unit is presented. It discusses about the implementation of supplementary prescribing (SPR) which aimed at...

  • …write a prescription.  // GP: General Practitioner;4/14/2006, p45 

    The article presents suggestions for general practitioners while writing prescriptions. Physicians are advised to use indelible ink, either completing by hand an FP10, or printing via a computer the FP10 Comp form from the computer. Include the patient's full name and address, plus age or date...

  • A Meta-Analysis of the Association between Adherence to Drug Therapy & Mortality.  // Professional Safety;Dec2006, Vol. 51 Issue 12, p46 

    The article presents a study about the significance of meta-analysis in drug therapy and mortality in the U.S. The study will allow safety, health and environmental professionals to seek knowledge about what happen when patient follow doctor's advice for taking drugs. Related study from various...

  • Rivaroxaban: a novel oral factor Xa inhibitor to prevent stroke in nonvalvular atrial fibrillation. Vitin, Leslie; Quinto, Emily; Kirwin, Jnnifer // Formulary;Jul2011, Vol. 46 Issue 7, p257 

    Rivaroxaban is an oral, direct factor Xa inhibitor under review by FDA for stroke prevention in patients with atrial fibrillation. Atrial fibrillation is the most common arrhythmia in the United States and conveys a 5-fold increased risk for stroke. Vitamin K antagonists, such as warfarin,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics